The Tysabri "rebound effect" refers to the phenomenon of people developing significantly more MS lesions in the months after they stop treatment than they had before they started.
I'll admit, I was a little reluctant to write this piece, as there is very little information in the medical literature. As far as I know, this has really only formally been studied in 2007, about a year and a half after Tysabri was withdrawn from market suddenly because the connection to PML was discovered.
Because there were suddenly a number of people who had all stopped at the same time, it was convenient to look at this group to see what happened to people who had been on Tysabri and stopped, which is what some Dutch researchers did. They identified the Tysabri "rebound effect."
I expected that all sorts of studies would follow, but I am unable to find any. I have found some recent work about Tysabri "drug holidays," looking at what happens in the short-term after stopping Tysabri, but none that look at the longer-term lesion burden or clinical consequences.
Therefore, I am sharing the article that I wrote, but also asking for anyone to send me additional information that they might have about the rebound effect. Whether you have personal experience or know of an article that I may have overlooked, let me know in the comments section, as I would love to shed more light on this situation. I really appreciate it.
Read the full article: The Tysabri Rebound Effect